Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has announced that its Annual General Meeting (AGM) will take place on 18 November 2025 at its office in Fitzroy, Victoria. The meeting will include an update from CEO Dr. Nina Webster, and the deadline for director nominations is set for 30 September 2025. This announcement is significant for stakeholders as it provides an opportunity for shareholders to receive updates on the company’s progress and strategic direction, particularly regarding its Phase 3 clinical developments.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company based in Victoria, Australia, specializing in the development of innovative therapies for unmet medical needs, particularly in inflammatory diseases. The company is focused on advancing its Phase 3 product candidate DMX-200 for treating Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory diseases, utilizing its proprietary Receptor Heteromer Investigation Technology (Receptor-HIT) platform.
Average Trading Volume: 1,555,373
Technical Sentiment Signal: Buy
Current Market Cap: A$315.1M
For an in-depth examination of DXB stock, go to TipRanks’ Overview page.